A102940 Stock Overview
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Kolon Life Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩22,900.00 |
| 52 Week High | ₩34,950.00 |
| 52 Week Low | ₩20,000.00 |
| Beta | 0.74 |
| 1 Month Change | -5.37% |
| 3 Month Change | -17.33% |
| 1 Year Change | -30.50% |
| 3 Year Change | -2.35% |
| 5 Year Change | -45.35% |
| Change since IPO | -15.79% |
Recent News & Updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12Recent updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26
Shareholder Returns
| A102940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.6% | 3.9% | 0.5% |
| 1Y | -30.5% | 8.3% | 4.7% |
Return vs Industry: A102940 underperformed the KR Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: A102940 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A102940 volatility | |
|---|---|
| A102940 Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A102940's share price has been volatile over the past 3 months.
Volatility Over Time: A102940's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 421 | Sun Jin Kim | www.kolonls.co.kr |
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters..
Kolon Life Science Inc. Fundamentals Summary
| A102940 fundamental statistics | |
|---|---|
| Market cap | ₩261.34b |
| Earnings (TTM) | -₩33.60b |
| Revenue (TTM) | ₩124.64b |
2.1x
P/S Ratio-7.8x
P/E RatioIs A102940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A102940 income statement (TTM) | |
|---|---|
| Revenue | ₩124.64b |
| Cost of Revenue | ₩112.34b |
| Gross Profit | ₩12.30b |
| Other Expenses | ₩45.90b |
| Earnings | -₩33.60b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.94k |
| Gross Margin | 9.87% |
| Net Profit Margin | -26.96% |
| Debt/Equity Ratio | 77.9% |
How did A102940 perform over the long term?
See historical performance and comparison